Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Venetoclax in Acute Myeloid Leukemia
share announcement

Venetoclax in Acute Myeloid Leukemia

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1716

Special Issue Editors

Dr. Mika Kontro

E-Mail Website
Guest Editor
1. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00100 Helsinki, Finland
2. Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, 00100 Helsinki, Finland
Interests: acute myeloid leukemia; drug resistance; response prediction; clinical trials; targeted therapies; BCL2 inhibitors
Dr. Heikki Kuusanmäki

E-Mail Website
Guest Editor
Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, 00100 Helsinki, Finland
Interests: acute myeloid leukemia; drug sensitivity profiling; response prediction; BH-3 mimetics; venetoclax; drug resistance
Dr. Martin Jädersten

E-Mail Website
Guest Editor
1. Department of Hematology, Karolinska University Hospital, 171 77 Stockholm, Sweden
2. Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden
Interests: acute myeloid leukemia; myelodysplastic syndrome; clinical trials; drug resistance; targeted therapies; BCL2 inhibitors

Special Issue Information

Dear Colleagues,

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with high morbidity and mortality rates. Despite significant advancements in treatment, AML remains a clinical challenge, and new therapeutic strategies are urgently needed to improve patient outcomes.

As guest editors of this Special Issue, we invite original research articles and reviews that showcase the latest research on the use of venetoclax in the treatment of AML, a highly selective BCL-2 inhibitor that has shown potent anti-leukemic activity in preclinical and clinical studies.

The articles in this Special Issue will cover the latest research on the use of venetoclax in combination with other agents, including novel targeted therapies, intensive chemotherapy, and immunomodulatory agents. We will also highlight emerging strategies for predicting treatment response.

We encourage researchers and clinicians to submit their original research articles and reviews to contribute to this Special Issue. We hope that the articles included in this Special Issue will be of interest to the readers of the journal and will contribute to ongoing efforts to improve the lives of patients with AML.

Dr. Mika Kontro
Dr. Heikki Kuusanmäki
Dr. Martin Jädersten
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myeloid leukemia (AML)
  • venetoclax
  • BCL-2 inhibitor
  • response prediction
  • combination therapy
  • targeted therapies

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 1182 KiB  
Review
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
by Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica and Marco Rossi
Cancers 2024, 16(1), 73; https://doi.org/10.3390/cancers16010073 - 22 Dec 2023
Viewed by 1455
Abstract
The combination approach based on venetoclax (VEN) with azacytidine (AZA) has significantly improved outcomes for elderly patients with acute myeloid leukemia (AML). This innovative approach has led to higher rates of overall response, measurable residual disease (MRD)-negative remissions, and overall survival compared with [...] Read more.
The combination approach based on venetoclax (VEN) with azacytidine (AZA) has significantly improved outcomes for elderly patients with acute myeloid leukemia (AML). This innovative approach has led to higher rates of overall response, measurable residual disease (MRD)-negative remissions, and overall survival compared with AZA monotherapy. As a result, this combination has emerged as the gold-standard treatment for elderly or unfit patients with AML who are not eligible for intensive therapy. In younger, fit patients with AML, intensive induction and consolidation chemotherapy is commonly used as a first-line approach; however, relapse continues to be the main reason for treatment failure in approximately 30–40% of patients. Efforts to improve MRD-negative response rates and to facilitate the transition to allogeneic hematopoietic stem cell transplantation, particularly in high-risk AML, have inspired trials exploring the combination of intensive chemotherapy with targeted agents. VEN, a first-in-class anti-BCL2 agent, combined with intensive chemotherapy regimens has shown deep MRD-negative remissions, producing prolonged event-free survival and enhancing the transition to allogeneic transplant in first-complete-remission patients. These benefits support the incremental advantages of adding VEN to intensive chemotherapy approaches across ELN risk subcategories, and provides a robust benchmark to design future trials. In this review, we will discuss current studies assessing the efficacy of frontline regimens integrating VEN into intensive chemotherapy in younger patients with AML and specific molecularly defined subgroups. Full article
(This article belongs to the Special Issue Venetoclax in Acute Myeloid Leukemia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop